Global HIV Drugs Market Size study, By Medication Class (Multi-class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Entry Inhibitors, and HIV Integrase Strand Transfer Inhibitors), and Regional Forecasts 2020-2027

Get in-depth COVID-19 impact and recovery analysis on the Global HIV Drugs Market

Flash Discount
15% Single User
20% Multi User
25% Corporate
30% Enterprise
  • Global HIV Drugs Market is valued approximately at USD 30.9 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 4.3% over the forecast period 2020-2027. Human Immunodeficiency Virus (HIV) is a chronic and life-threatening disease that can be transmitted from one person to another through blood-to-blood and sexual contact. It is a virus that destroys immune cells known as CD-4 cells, rendering the body vulnerable to infections and other diseases. Over the years, the growing prevalence of HIV disease worldwide has had a positive effect on demand for HIV drugs. HIV medications help prevent the spread of HIV, thereby reducing the risk of transmission of HIV. Significant factors that fuel the growth of the HIV drug market include an increase in HIV prevalence and an increase in the rate of care and diagnosis. In addition, there is an increase in government initiatives to raise awareness among people about the cause of HIV, symptoms, available treatment options, and the critical role of these treatments in controlling the growth of the HIV virus. As a result, awareness-raising through such government programs is also expected to improve the demand for HIV drugs. However, strict government regulations for the approval and sale of HIV drugs are likely to limit the development of the HIV drug industry. The factors responsible for increasing prevalence include unsafe sex, infected needles or syringes, and, lack of knowledge of the mode of transmission. The concerted efforts of the government and various NGOs to provide at-risk individuals with greater exposure to disease testing and care for infected persons are a key driver of the growth of the HIV-1 industry. In addition, the advent of generic drugs, which are cost-effective and chemically like branded drugs, is another factor adding to the demand for HIV drugs. According to WHO, 37.9 million people were diagnosed with HIV/AIDS in 2018, globally, while 1.1 million died of AIDS-related illness in the same year. A variety of community awareness programmes and education campaigns have been initiated by federal government agencies and numerous organizations across the globe to combat HIV prevention, treatment and care.

    The regional analysis of global HIV Drugs Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America, and Rest of the World. Asia-Pacific offers lucrative prospects for key players on the HIV drug market due to a rise in population and a high increase in geriatric population. In addition, the increase in health expenditure and the production of guidelines are expected to fuel market growth in the region.

    Major market player included in this report are:

    Boehringer Ingelheim International GmbH

    Merck & Co., Inc.

    ViiV Healthcare


    F. Hoffmann-La Roche Ltd.

    Teva Pharmaceutical Industries Ltd.

    Bristol-Myers Squibb

    Gilead Sciences, Inc.

    Johnson & Johnson

    Cipla Limited

    Daiichi Sankyo


    Hetero Drugs


    The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-
    segment of the market are explained below:

    By Medication Class:

    Multi-class Combination Drugs

    Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

    Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

    Protease Inhibitors (P0Is)

    Entry Inhibitors

    HIV Integrase Strand Transfer Inhibitors

    By Region:

    North America










    Asia Pacific





    South Korea


    Latin America



    Rest of the World

    Furthermore, years considered for the study are as follows:

    Historical year – 2017, 2018

    Base year – 2019

    Forecast period – 2020 to 2027

    Target Audience of the Global HIV Drugs Market in Market Study:

    Key Consulting Companies & Advisors

    Large, medium-sized, and small enterprises

    Venture capitalists

    Value-Added Resellers (VARs)

    Third-party knowledge providers

    Investment bankers



  • With tables and figures helping analyze worldwide Global HIV Drugs market, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

    Chapter 1. Executive Summary
    1.1. Market Snapshot
    1.2. Global & Segmental Market Estimates & Forecasts, 2018-2027 (USD Billion)
    1.2.1. HIV Drugs Market, by Region, 2018-2027 (USD Billion)
    1.2.2. HIV Drugs Market, by Medication Class, 2018-2027 (USD Billion)
    1.3. Key Trends
    1.4. Estimation Methodology
    1.5. Research Assumption
    Chapter 2. Global HIV Drugs Market Definition & Scope
    2.1. Objective of the Study
    2.2. Market Definition & Scope
    2.2.1. Scope of the Study
    2.2.2. Industry Evolution
    2.3. Years Considered for the Study
    2.4. Currency Conversion Rates
    Chapter 3. Global HIV Drugs Market Dynamics
    3.1. HIV Drugs Market Impact Analysis (2018-2027)
    3.1.1. Market Drivers
    3.1.2. Market Challenges
    3.1.3. Market Opportunities
    Chapter 4. Global HIV Drugs Market: Industry Analysis
    4.1. Porter’s 5 Force Model
    4.1.1. Bargaining Power of Suppliers
    4.1.2. Bargaining Power of Buyers
    4.1.3. Threat of New Entrants
    4.1.4. Threat of Substitutes
    4.1.5. Competitive Rivalry
    4.1.6. Futuristic Approach to Porter’s 5 Force Model (2017-2027)
    4.2. PEST Analysis
    4.2.1. Political
    4.2.2. Economical
    4.2.3. Social
    4.2.4. Technological
    4.3. Investment Adoption Model
    4.4. Analyst Recommendation & Conclusion
    Chapter 5. Global HIV Drugs Market, by Medication Class
    5.1. Market Snapshot
    5.2. Global HIV Drugs Market by Medication Class, Performance - Potential Analysis
    5.3. Global HIV Drugs Market Estimates & Forecasts by Medication Class, 2017-2027 (USD Billion)
    5.4. HIV Drugs Market, Sub Segment Analysis
    5.4.1. Multi-class Combination Drugs
    5.4.2. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
    5.4.3. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    5.4.4. Protease Inhibitors (P0Is)
    5.4.5. Entry Inhibitors
    5.4.6. HIV Integrase Strand Transfer Inhibitors
    Chapter 6. Global HIV Drugs Market, Regional Analysis
    6.1. HIV Drugs Market, Regional Market Snapshot
    6.2. North America HIV Drugs Market
    6.2.1. U.S. HIV Drugs Market Medication Class breakdown estimates & forecasts, 2017-2027
    6.2.2. Canada HIV Drugs Market
    6.3. Europe HIV Drugs Market Snapshot
    6.3.1. U.K. HIV Drugs Market
    6.3.2. Germany HIV Drugs Market
    6.3.3. France HIV Drugs Market
    6.3.4. Spain HIV Drugs Market
    6.3.5. Italy HIV Drugs Market
    6.3.6. Rest of Europe HIV Drugs Market
    6.4. Asia-Pacific HIV Drugs Market Snapshot
    6.4.1. China HIV Drugs Market
    6.4.2. India HIV Drugs Market
    6.4.3. Japan HIV Drugs Market
    6.4.4. Australia HIV Drugs Market
    6.4.5. South Korea HIV Drugs Market
    6.4.6. Rest of Asia Pacific HIV Drugs Market
    6.5. Latin America HIV Drugs Market Snapshot
    6.5.1. Brazil HIV Drugs Market
    6.5.2. Mexico HIV Drugs Market
    6.6. Rest of The World HIV Drugs Market
    Chapter 7. Competitive Intelligence
    7.1. Top Market Strategies
    7.2. Company Profiles
    7.2.1. Boehringer Ingelheim International GmbH Key Information Overview Financial (Subject to Data Availability) Industry Summary Recent Developments
    7.2.2. Merck & Co., Inc.
    7.2.3. ViiV Healthcare
    7.2.4. AbbVie
    7.2.5. F. Hoffmann-La Roche Ltd.
    7.2.6. Teva Pharmaceutical Industries Ltd.
    7.2.7. Bristol-Myers Squibb
    7.2.8. Gilead Sciences, Inc.
    7.2.9. Johnson & Johnson
    7.2.10. Cipla Limited
    7.2.11. Daiichi Sankyo
    7.2.12. Emcure
    7.2.13. Hetero Drugs
    7.2.14. Mylan
    Chapter 8. Research Process
    8.1. Research Process
    8.1.1. Data Mining
    8.1.2. Analysis
    8.1.3. Market Estimation
    8.1.4. Validation
    8.1.5. Publishing
    8.2. Research Attributes
    8.3. Research Assumption


  • The Global HIV Drugs Market has been segregated into various crucial divisions including applications, types, and regions. Each market segment is intensively studied in the report contemplating its market acceptance, worthiness, demand, and growth prospects. The segmentation analysis will help the client to customize their marketing approach to have a better command of each segment and to identify the most prospective customer base.

    Report Objectives / Segmentation Covered :
    By Companies / players:
    • Boehringer Ingelheim International GmbH Merck & Co.
    • Inc. ViiV Healthcare AbbVie F. Hoffmann-La Roche Ltd. Teva Pharmaceutical Industries Ltd. Bristol-Myers Squibb Gilead Sciences
    • Inc. Johnson & Johnson Cipla Limited Daiichi Sankyo Emcure Hetero Drugs Mylan
    By Regions:
    • North America
    • U.S.
    • Canada
    • Europe
    • UK
    • Germany
    • France
    • Spain
    • Italy
    • ROE
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • RoAPAC
    • Latin America
    • Brazil
    • Mexico
    • Rest of the World
    By Type:
      By Application:
      Licensing options

      Need assistance ?

      Related reports

      Research objectives

      Where will all these developments take the industry in the long

      To study and analyze the global Market consumption (value & volume) by key regions/countries, product type and application, history data from 2015 to 2019, and forecast to 2025.

      What are the future opportunities in the market?

      To understand the structure of Market by identifying its various subsegments.

      What are the major driving forces expected to impact the development of the market market across different regions?

      To analyze the market with respect to individual growth trends, future prospects, and their contribution to the total market.

      Which industry trends are likely to shape the future of the industry during the forecast period 2020-2025?

      To project the consumption of market submarkets, with respect to key regions.

      Who are the major driving forces expected to decide the fate of the industry worldwide.

      To strategically profile the key players and comprehensively analyze their growth strategies.

      What are the key barriers and threats believed to hinder the development of the industry?

      To analyze competitive developments such as expansions,agreements, new product launches, and acquisitions in the market.

      Who are the prominent market players making a mark in the market with their winning strategies?

      To share detailed information about the key factors influencing the growth of the market

      What will be the growth rate and the market size of the industry for the forecast period 2020-2025?

      Focuses on the key global market Vendors, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.

      Our Clients